PDCD1 and hepatocellular carcinoma: Now, several anti-PD-1 antibodies have been approved by the Food and Drug Administration (FDA) such as nivolumab which was permitted to treat patients with advanced HCC for the second-line approach, and pembrolizumab which was also favored to use in the patients diagnosed at advanced stages [9, 10].